Pharmacology-AI’s Personalized Medicine and Drug Discovery Data Analytics Business
First written in FY2024-Q1. 4 of 6 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「As a specific initiative, we launched “ReproRegistry,” a UK-based medical volunteer registration system. It identifies candidates best suited to clinical trials with high precision in cooperation with Pharmacology-AI, and we intend to make it the core platform for our next-generation clinical trial support business.」
The company has reaffirmed its policy of building a personalized medicine and clinical trial support business by linking Pharmacology-AI with ReproRegistry. - FY2026-H1AdvancedAnnual report
「As a specific initiative, we launched “ReproRegistry,” a UK-based medical volunteer registration system. It identifies candidates best suited to clinical trials with high precision in cooperation with Pharmacology-AI, and we intend to make it the core platform for our next-generation clinical trial support business.」
As part of the commercialization of Pharmacology-AI, the company launched ReproRegistry, a medical volunteer registration system for identifying clinical trial candidates, adding a concrete platform for clinical trial support. - FY2025-H1RestatedAnnual report
「Going forward, we will launch new businesses using Pharmacology-AI for data analysis related to personalized medicine and big data analysis related to drug development.」
The company has reaffirmed its policy of commercializing new businesses involving personalized medicine data analysis and big data analysis for drug development using Pharmacology-AI. - FY2024-Q3RestatedAnnual report
「REPROCELL EU successfully developed Pharmacology-AI, a machine-learning platform for personalized medicine, jointly with IBM Research and the UK’s STFC Hartree Centre. Going forward, we will launch new businesses using Pharmacology-AI for data analysis related to personalized medicine and big data analysis related to drug development.」
The company has reaffirmed its policy of commercializing new businesses involving personalized medicine data analysis and big data analysis for drug development using Pharmacology-AI. - FY2024-Q2RestatedAnnual report
「REPROCELL EU successfully developed Pharmacology-AI, a machine-learning platform for personalized medicine, jointly with IBM Research and the UK’s STFC Hartree Centre. Going forward, we will launch new businesses using Pharmacology-AI for data analysis related to personalized medicine and big data analysis related to drug development.」
The company has reaffirmed its policy of commercializing new businesses involving personalized medicine data analysis and big data analysis for drug development using Pharmacology-AI. - FY2024-Q1First statedAnnual report
「REPROCELL EU successfully developed Pharmacology-AI, a machine-learning platform for personalized medicine, jointly with IBM Research and the UK’s STFC Hartree Centre. Going forward, we will launch new businesses using Pharmacology-AI for data analysis related to personalized medicine and big data analysis related to drug development.」
Through joint development with IBM Research and the UK’s STFC Hartree Centre, the company developed a machine-learning platform for personalized medicine and plans to commercialize new businesses involving data analysis and big data analysis for drug development.